FDA 483 - Englewood Lab Korea Co., Ltd. - October 25, 2024

An FDA inspection of Englewood Lab Korea Co., Ltd., an OTC pharmaceutical manufacturer, revealed three significant observations. These included deficiencies in microbiological testing of components, failure to fully follow quality control unit procedures, and inadequate recording and justification of deviations from production and process control procedures, specifically regarding actions to prevent reoccurrence.